Metformin, The Biguanide Derivative, as Adjuvant Therapy in Patients With Ulcerative Colitis Treated With Mesalamine

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that is marked by increased intestinal motility and bloody diarrhea. The clinical value of existing therapeutic strategies of UC, including glucocorticoids, anti-tumor necrosis factor α (TNF-α), mesalamine, and thiopurines is still limited. Therefore, the discovery of new therapeutic approaches is essential to improve the effectiveness of the treatment.Adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a conserved fuel-sensing enzyme that plays an important role in the regulation of cellular metabolism where it increases glucose and fatty acids uptake and activates the oxidation process to improve the cellular energy utilization

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• \- Age ≥ 18 years Both males and females will be included Negative pregnancy test and effective contraception Mild and moderate UC patients diagnosed and confirmed by the endoscope

Locations
Other Locations
Egypt
Faculty of Medicine, Mansoura University
RECRUITING
Al Mansurah
Contact Information
Primary
Mostafa Bahaa, PhD
mbahaa@horus.edu.eg
0201025538337
Time Frame
Start Date: 2023-01-20
Estimated Completion Date: 2027-04
Participants
Target number of participants: 46
Treatments
No_intervention: Control Group
This group will take mesalamine 1 g three times daily
Active_comparator: Metformin group
This group will take mesalamine 1 g three times daily plus metformin 500 mg two times daily
Sponsors
Leads: Tanta University
Collaborators: Principal Investigator Mostafa Mahmoud Bahaa El-Dien Pharmacy Practice Department- Horus University

This content was sourced from clinicaltrials.gov